1. Home
  2. CBIO vs NGS Comparison

CBIO vs NGS Comparison

Compare CBIO & NGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

N/A

Current Price

$17.97

Market Cap

482.6M

Sector

N/A

ML Signal

N/A

Logo Natural Gas Services Group Inc.

NGS

Natural Gas Services Group Inc.

N/A

Current Price

$43.88

Market Cap

475.1M

Sector

Energy

ML Signal

N/A

Company Overview

Basic Information
Metric
CBIO
NGS
Founded
2003
1998
Country
United States
United States
Employees
44
N/A
Industry
Oilfield Services/Equipment
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
482.6M
475.1M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
CBIO
NGS
Price
$17.97
$43.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
3
Target Price
$26.67
$40.67
AVG Volume (30 Days)
240.6K
102.2K
Earning Date
04-29-2026
05-11-2026
Dividend Yield
N/A
1.08%
EPS Growth
N/A
14.60
EPS
N/A
0.53
Revenue
N/A
$172,315,000.00
Revenue This Year
N/A
$15.05
Revenue Next Year
$279.20
$9.52
P/E Ratio
N/A
$83.26
Revenue Growth
N/A
9.94
52 Week Low
$8.72
$22.72
52 Week High
$27.41
$44.27

Technical Indicators

Market Signals
Indicator
CBIO
NGS
Relative Strength Index (RSI) 43.06 58.76
Support Level $17.02 $38.57
Resistance Level $19.05 $43.98
Average True Range (ATR) 1.20 1.53
MACD -0.06 0.22
Stochastic Oscillator 27.11 81.45

Price Performance

Historical Comparison
CBIO
NGS

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About NGS Natural Gas Services Group Inc.

Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.

Share on Social Networks: